PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

被引：0
|
作者：
Ming Chen
Jinlian Zhu
Xuedong Yang
Jianxin Yao
Yuqing Liu
Qiang Liu
机构：
[1] Changshu No.2 People’s Hospital,Department of Hematology
[2] Changshu No.2 People’s Hospital,Department of Oncology
[3] Changshu No.1 People’s Hospital,Department of Hematology
来源：
European Journal of Medical Research | / 27卷
关键词：
Relapsed/refractory multiple myeloma; T cell subtype; PD-1; LAG-3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients
    Chen, Ming
    Zhu, Jinlian
    Yang, Xuedong
    Yao, Jianxin
    Liu, Yuqing
    Liu, Qiang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [2] PD-1 and LAG-3 positive T cells are related with the prognosis of patients with chronic kidney disease
    Jiang, Hongwei
    Wu, Jing
    Zhang, Junlin
    EXPERIMENTAL CELL RESEARCH, 2024, 438 (01)
  • [3] Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
    Hossain, Shahrier
    Mo, Clifton
    Patches, Sarah
    Leblebjian, Houry
    Goodrich, Kathryn
    Regan, Eileen
    O'Neill, Kathleen
    Noonan, Kim
    Richardson, Paul G.
    Laubach, Jacob
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, : 982 - 989
  • [4] Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
    Catamero, Donna
    Ray, Chloe
    Purcell, Kiah
    Leahey, Sheryl
    Esler, Elaine
    Rogers, Stephanie
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Tolbert, Jaszianne
    Renaud, Thomas
    Patel, Saurabh
    Hannemann, Linda
    Shenoy, Samantha
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (05)
  • [5] Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review
    Khan, Wardah Javed
    Ali, Mubeen
    Hashim, Sana
    Nawaz, Huma
    Hashim, Syeda Nafeesa
    Safi, Danish
    Inayat, Arslan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 552 - 561
  • [6] The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma
    Kreiniz, Natalia
    Eiza, Nasren
    Tadmor, Tamar
    Yurkovski, Ilana Levy
    Greenfeld, Sarah Matarasso
    Sabag, Adi
    Mubariki, Raeda
    Suriu, Celia
    Votinov, Ekaterina
    Toubi, Elias
    Vadasz, Zahava
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [7] Enrichment of LAG-3, but not PD-1, on Double Negative T Cells at the Female Genital Tract
    Juno, Jennifer A.
    Lajoie, Julie
    Stalker, Andrew T.
    Oyugi, Julius
    Kimani, Makobu
    Kimani, Joshua
    Plummer, Francis A.
    Fowke, Keith R.
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2014, 72 (06) : 534 - 540
  • [8] Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
    Lichtenegger, Felix S.
    Rothe, Maurine
    Schnorfeil, Frauke M.
    Deiser, Katrin
    Krupka, Christina
    Augsberger, Christian
    Schlueter, Miriam
    Neitz, Julia
    Subklewe, Marion
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [9] The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy
    Du, Huimin
    Yi, Ziying
    Wang, Long
    Li, Zhi
    Niu, Bailin
    Ren, Guosheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 78
  • [10] How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
    Sonneveld, Pieter
    De Wit, Edwin
    Moreau, Philippe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 153 - 170
12345